Using SWATH® Acquisition to understand the impact on the Proteome of CRISPR gene editing
Date: 11 June | Time: 3PM London/10AM New York
Using SWATH® Acquisition to understand the impact on the Proteome of CRISPR gene editing
Date: 11 June | Time: 3PM London/10AM New York
Already Registered?
If you have previously registered for this event, please login below:
Register your details belowCobo Tecnologies PIPPR® platform has been specifically designed to understand, at the proteome level, the changes caused by CRISPR genetic editing of cell lines, whether of animal or plant origin. PIPPR platform includes large-scale proteomics expression analysis using SCIEX SWATH® Acquisition mass spectrometry. SWATH® Acquisition allows the identification and quantification of 3000 to 5000 proteins in any cell line, therefore detecting expression changes when comparing modified vs. wildtype cells. PIPPR® bioinformatics also include the analysis of pathways, gene ontology terms, and protein networks altered by the DNA edition. Since it is a non-targeted approach, not only the expression of the edited gene is monitored, but also the proteins showing differential expression in the same pathways and networks, and even off-target changes, can be detected.
On this webinar, we will show two pilot experiments from Lundbeck, one showing the use of SWATH® Acquisition-based proteomics pilot in assessing CRISPR-based knock-out and second showing the usefulness of SWATH® Acquisition to study full proteome in disease-relevant model systems.
Presented by
Jens-Ole Bock,
CEO and Co-founder of COBO Technologies
Jens-Ole Bock is CEO and Co-founder of the fast growing CRO, COBO Technologies, that supports the growing need for more quality control in genome editing. The company focus is, InDel mutation analysis and proteomic profiling using SWATH® Acquisition. In addition Bock is also advisor for CRISPR Medicine News, that post weekly interviews from the CRISPR medicine field.
Bock comes with a solid background in molecular biology from the University of Copenhagen, Denmark. He has more than 18 years of commercial experience working with some of the leading genome-editing companies in the world. Bock successfully introduced the first commercially available genome editing tool, the Zinc Finger Nuclease (ZFN), in Europe as part of the specialist team at Sigma-Aldrich. He has done more than 100 presentations at conferences, seminars, and meetings in Europe, the US, and Asia. Jens-Ole Bock also supports the Danish start-up environment as an advisor and as a board member.
Michal Lubas,
Senior Scientist at Lundbeck A/S and University of Southern Denmark
Michal Lubas is a Senior Scientist at Lundbeck A/S and University of Southern Denmark.
He has hands-on experience in omics methods that he has over the past years applied in multiple biological systems. Proteomics has been his method of choice for mapping protein-protein interactions and identifying changes at the protein level.
Currently, Michal‘s research focuses on mechanisms underlying pathologies observed in Parkinson’s and Alzheimer’s diseases.
Key Learning Objectives
- PIPPR® platform is specifically designed to understand what is going on inside the cells that have been genetically modified.
- The full PIPPR® workflow includes sample preparation, large-scale proteomics expression analysis, and downstream bioinformatics analysis for biological interpretation of results.
- PIPPR® bioinformatics include the analysis of pathways, gene ontology terms, and protein networks affected by the DNA edition.
- On those experiments, different changes have been targeted after CRISPR gene editing that cannot be described with transcriptome analysis.
Audience
- Heads of Research Development
- Heads of Gene Editing
- CRISPR Development
- Project Managers
- Technicians